HDAC11: a rising star in epigenetics - 28/10/20
pages | 7 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Graphical Abstract |
Highlights |
• | HDAC11 is the latest member of histone deacetylase family. |
• | HDAC11 is closely associated with tumor development and prognosis. |
• | HDAC11 is involved in the biological functions of almost every system of the human body. |
• | Highly selective inhibitors are essential to study the biological function of HDAC11. |
Abstract |
Epigenetic mechanisms, such as acetylation, methylation, and succinylation, play pivotal roles in the regulation of multiple normal biological processes, including neuron regulation, hematopoiesis, bone cell maturation, and metabolism. In addition, epigenetic mechanisms are closely associated with the pathological processes of various diseases, such as metabolic diseases, autoimmune diseases and cancers. Epigenetic changes may precede genetic mutation, so research on epigenetic changes and regulation may be important for the early detection and diagnosis of disease. Histone deacetylase11 (HDAC11) is the newest member of the histone deacetylase (HDAC) family and the only class IV histone deacetylase. HDAC11 has different expression levels and biological functions in different systems of the human body and is among the top 1 to 4% of genes overexpressed in cancers, such as breast cancer, hepatocellular carcinoma and renal pelvis urothelial carcinoma. This article analyzes the role and mechanism of HDAC11 in disease, especially in tumorigenesis, in an attempt to provide new ideas for clinical and basic research.
Le texte complet de cet article est disponible en PDF.Keywords : HDAC11, epigenetics, pathophysiological, disease, cancer
Plan
Vol 131
Article 110607- novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?